Development and In-Vitro Characterization of Ca-Alginate Beads of Oxytetracycline Hydrochloride for Oral Use: Effect of Process Variables

Lalit Kumar Tyagi^1, , Ravi Shekhar², Kalpesh Gaur³ and Mohan Lal Kori⁴

¹Guru Nanak Institute of Pharmacy, Dalewal, Hoshiarpur, Punjab, India

²Department of Pharmacy, Dr B R Ambedker University, Khandari Campus, Agra, Uttar Pradesh, India

³Geetanjali Institute of Pharmacy, Geetanjali University, Manwa Khera, Udaipur, Rajasthan, India

⁴Vedica College of B. Pharmacy, A Constituent Institute of RKDF University, Bhopal, Madhya Pradesh, India

Cite this paper:
Lalit Kumar Tyagi, Ravi Shekhar, Kalpesh Gaur and Mohan Lal Kori. Development and In-Vitro Characterization of Ca-Alginate Beads of Oxytetracycline Hydrochloride for Oral Use: Effect of Process Variables. American Journal of Pharmacological Sciences. 2017; 5(3):63-70. doi: 10.12691/ajps-5-3-2

Abstract

This work investigates the preparation of Oxytetracycline Hydrochloride loaded alginate beads to take advantage of the swelling properties of alginate beads for improving the oral delivery. Variations in polymer concentration, concentration of cross-linking agent and cross-linking time were examined systemically for their effects on the particle size, entrapment efficiency, percent yield, flow properties and In vitro drug release behavior. Calcium alginate (Ca-alginate) beads of Oxytetracycline hydrochloride were prepared by ionic-gelation method. Shape and surface characteristics were determined by scanning electron microscopy (SEM). Average particle size of drug-loaded beads was determined by sieving method. In vitro drug release behavior from Ca-alginate beads were carried out in simulated gastric fluid (SGF) for first 2 h and simulated intestinal fluid (SIF) for the next 6 h. SEM confirmed spherical shape of beads with rough and porous morphology. The average particle size of the beads was in the range of 470.96 ± 15.22 to 709.33 ± 16.28 µm. Results indicated that the average particle size and flow property of the beads increased with an increase in the concentration of polymer and the cross-linking agent as well as the cross-linking time. The entrapment efficiency and percentage yield was found to be in the range of 52.87 ± 1.56 to 61.76 ± 0.96 % and 69.98 ± 0.33 to 78.94 ± 0.43 % respectively. Concentration of the sodium alginate up to 1.75 % w/v, cross-linker concentration up to 2 % w/v and cross-linking time (30 min) shows highest percent entrapment efficiency (61.76 ± 0.96 %) and % yield (78.94 ± 0.43 %). A decrease in the rate and extent of drug release was observed with relative increase in the polymer concentration, cross- linker concentration and cross-linking time. No significant drug-polymer interaction was observed in DSC study. From this study it can be concluded that the natural polymer sodium alginate can prolong the release of Oxytetracycline Hydrochloride.

Keywords:
calcium alginate beads Oxytetracycline Hydrochloride in vitro drug release

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Kim CK, Lee EJ. The controlled release of blue dextran from alginate beads. Int J Pharm 1992; 79: 11-19.
[2]	El-Kamal AH, Al-Gohary OM, Hosny EA. Alginate-diltiazem hydrochloride beads: optimization of formulation factors, in vitro and in vivo availability. J Microencapsul 2003; 20: 211-225.
[3]	Heng P, Chan L, Wong T. Formation of alginate microspheres produced using emulsification technique. J Microencapsul 2003; 20: 401-413.
[4]	George M, Abraham TE. Poly-ionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan- A review. J Control Rel 2006; 114: 1-14.
[5]	Gombotz W, Wee S. Protein release from alginate matrices. Adv Drug Deliv Rev 1998;31: 267-285.
[6]	Olszewska M. Oxytetracycline mechanism of action and application in skin diseases. Wiad Lek 2006; 59: 829-833.
[7]	Sweetman SC. Martindale: The complete drug reference. 33rd ed. The Pharmaceutical Press 2002; 258-260.
[8]	Rodriguez MLG, Holgado MA, Lafuente CS, Rabasco AM, Fini A. Alginate/chitosan particulate systems for sodium diclofenac release. Int J Pharm 2002; 232: 225-234.
[9]	Takeshita S, Sugawara S, Imai T, Otagiri M. Preparation and evaluation of controlled release formulation of nefedepine using alginate beads. Biol Pharm Bull 1993; 16: 420-424.
[10]	Mishra B, Jayanth P, Sankar C. Development of chitosan-alginate microcapsules for colon specific delivery of metronidazole. Indian Drugs 2003; 40: 695-700.
[11]	Aulton ME. Pharmaceutics: The science of dosage form design. 2nd ed. Churchill Livingston, New York 2002; 197-210.
[12]	Vijaya DR, Razzak M, Tucker IG, Medlicott NJ. Encapsulation of vitamin B12 into polylactide (ε-caprolactone) microparticles using w-o-w emulsion system. Indian Drugs 2006; 43: 457-461.
[13]	Soppimath K, Kulkarni A, Aminabhavi T. Encapsulation of antihypertensive drugs in cellulose-based matrix microspheres: characterization and release kinetics of microspheres and tableted microspheres. J Microencapsul 2001; 18: 397-409.
[14]	El-Gibaly I. Oral delayed-release system based on Zn-pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery. Int J Pharm 2002; 232: 199-211.
[15]	Arica B, Calis S, Atilla P, Durlu N, Cakar N, Kas H, Hincal A. In vitro and in vivo studies of ibuprofen-loaded biodegradable alginate beads. J Microencapsul 2005; 22: 153-165.
[16]	Carr R. Evaluating flow properties of solids. Chem Eng 1965; 18: 163-168.
[17]	Hausner H. Friction conditions in a mass metal powder. Int J Powder Metall 1967; 3: 7-13.
[18]	Rastogi R, Sultana Y, Aqil M, Ali A, Kumar S, Chuttani K, Mishra AK. Alginate microspheres of isoniazid for oral sustained drug delivery. Int J Pharm 2007; 334: 71-77.
[19]	Lin S, Ayres J. Calcium alginate beads as core carriers of 5-aminosalisylic acid. Pharm Res 1992; 9: 1128-1131.
[20]	Gaudio P, Colombo P, Colombo G, Russo P, Sonvico F. Mechanisms of formation and disintegration of alginate beads obtained by prilling. Int J Pharm 2005; 302: 1-9.
[21]	Al-Kassaa RS, Al-Gohary OMN, Al-Faadhel MM. Controlling of systematic absorption of gliclazide through incorporation into alginate beads. Int J Pharm 2007; 341: 230-237.